3 results
Approved WMOCompleted
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients (no prior exposure to factor products or any blood products) of less than 6 years of age.
Approved WMORecruiting
The study aims to evaluate a modified Anti-Platelet Therapy, when associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy.. The modified antiplatelet therapy consists…
Approved WMORecruiting
To determine wheter the use of the taurolidine 1.35%, citrate 4%, and heparin 100 IU/ml lock solution (TauroLock*-Hep100) reduces the incidence of first tunneled central line associated bloodstream inections (CLABSI) compared to the heparin 100 IU/…